Compelling indications for specific drug classes*
| Indication | Drug class |
|---|---|
| Diabetes with nephropathy | ACE inhibitor or angiotensin-receptor blocker (30), (31) |
| Nondiabetic chronic kidney disease with proteinuria | ACE inhibitor or angiotensin-receptor blocker if patient is ACE-intolerant (32) |
| Coronary artery disease | ACE inhibitor or angiotensin-receptor blocker; (33), (34) β-blocker (35) |
| Heart failure with reduced ejection fraction | ACE inhibitor or angiotensin-receptor blocker; (36), (37) β-blocker; (38) mineralocorticoid-receptor antagonist given to select patients depending on their clinical presentation (recent hospital admission because of a cardiovascular event, acute myocardial infarction, elevated level of B-type natriuretic peptide or N-terminal pro-brain natriuretic peptide, or New York Heart Association class II–IV heart failure (29) |
| Previous stroke or transient ischemic attack | Combination of an ACE inhibitor and a diuretic (39) |
Note: ACE = angiotensin-converting enzyme.
↵* According to the Canadian Hypertension Education Program, (11) these drugs are considered to have compelling indications for use because of their ability to reduce mortality, cardiovascular morbidity or renal morbidity.